Prevention of antibiotic‐associated diarrhea in children by <i>Clostridium butyricum</i> MIYAIRI

Seki, Hiromi; Shiohara, Masaaki; Matsumura, Tadao; Miyagawa, Natsuki; Tanaka, Mamoru; Komiyama, Atsushi; Kurata, S

doi:10.1046/j.1442-200x.2003.01671.x

Cited by 204 publications

(167 citation statements)

References 7 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…It produces large quantities of short-chain fatty acids (SCFAs) (deVos et al, 2009), especially butyrate, and an active bacteriocin (Nakanishi & Tanaka, 2010); it also sporulates, allowing it to resist antibiotics that may disrupt other gut flora. It has previously shown effectiveness in the prophylaxis of CDAD in a mouse model (Kamiya et al, 1997) and in a clinical trial for prevention of antibiotic-associated diarrhoea in paediatric patients (Seki et al, 2003). In another clinical trial, CBM588 significantly reduced the incidence of detection of C. difficile toxin in the stools of patients taking Helicobacter pylori-eradication therapy (Imase et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain

Woo

Oka²,

Takahashi³

et al. 2011

Journal of Medical Microbiology

View full text Add to dashboard Cite

In contrast to most modern pharmaceuticals, probiotics are used in many parts of the world with little or no research data on the complex system of interactions that each strain may elicit in the human body. Research on probiotics has recently become more significant, as probiotics have begun to be prescribed by clinicians as an alternative for some gut infections, especially when antibiotics are contraindicated. This study attempted to elucidate the inhibitory interaction between the Japanese probiotic strain Clostridium butyricum MIYAIRI 588 (CBM588) and the hospital pathogen Clostridium difficile, which is responsible for a large proportion of antibioticassociated diarrhoea and colitis. CBM588 has previously shown effectiveness against C. difficile in vivo, and here it was found that the toxicity of C. difficile in in vitro co-culture with CBM588 was greatly decreased or absent. This was dependent on the inoculation ratio and was not accounted for by the small degree of growth and mRNA inhibition observed. CBM588 and its cell-free supernatant also had no effect on toxin already secreted into the culture medium, and culture of the two strains separated by a semi-permeable membrane resulted in loss of the inhibition. Therefore, it was concluded that the detoxification probably occurred by the inhibition of toxin protein production and that this required close proximity or contact between the two species. The low-pH conditions caused by organic acid secretion were also observed to have inhibitory effects on C. difficile growth, metabolism and toxicity.

show abstract

Section: Introductionmentioning

confidence: 99%

Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain

Woo

Oka²,

Takahashi³

et al. 2011

Journal of Medical Microbiology

View full text Add to dashboard Cite

show abstract

“…Clostridium butyricum is a typical butyric acid-producing, spore-forming, gram-positive anaerobe, which is found in soil and in the intestines of healthy humans and animals. This C. butyricum is a probiotic bacteria used clinically to prevent disturbances of gastrointestinal microbiota, to treat diarrhea, to enhance humoral immune response and to promote digestion in humans (Ito et al, 1997;Seki et al, 2003;Isono et al, 2007). Our previous experiments demonstrated that fish oil diets reduced abdominal fat in broiler chickens, whereas C. butyricum supplementation increased intramuscular fat content in breast muscle (Yang et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

Effects of dietary lipids and Clostridium butyricum on serum lipids and lipid-related gene expression in broiler chickens

Zhang

Yang

Guo

et al. 2011

Animal

View full text Add to dashboard Cite

The effect of dietary lipids and Clostridium butyricum supplementation on circulating lipids and the transcription of selected genes involved in lipid metabolism were investigated in broiler chickens. One hundred and sixty-day-old broilers (Arbor Acres) were divided into four treatment groups in a 2 3 2 factorial arrangement and fed four diets with two lipid sources (soybean oil or fish oil) and two levels of C. butyricum (0 or 5 g/kg) for a period of 6 weeks. Serum concentrations of total cholesterol and low-density lipoprotein cholesterol were lower (P , 0.05) in broilers fed diets containing fish oil than in those fed diets containing soybean oil. Fish oil significantly reduced (P , 0.05) hepatic fatty acid synthase and lipoprotein lipase (LPL) activities in abdominal fat. In contrast, fish oil significantly increased (P , 0.05) breast muscle LPL activity and hepatic peroxisome proliferator-activated receptor-a and LPL gene expression. The addition of C. butyricum significantly increased (P , 0.05) LPL activity in abdominal fat and liver-type fatty acid-binding protein gene expression in jejunal mucosa. The results of this study indicated that the reduced abdominal fat in broilers fed fish oil as observed may be due to augmented hepatic fatty acid catabolism and lower hepatic fat synthesis. The increased intramuscular fat content in breast muscle of broilers fed C. butyricum as described may be the result of enhanced fatty acid uptake.

show abstract

“…Seki et al 36 investigated the behavior of the microbiota in the use of antimicrobials with or without the use of probiotics. They classified 110 children and teenagers between 1 month and 15 years of age, according to three groups: those who received only antimicrobial treatment, those who initiated the use of probiotics during antibiotic treatment, and those who combined probiotic and antimicrobial from the beginning of the treatment.…”

Section: Conflict Of Interest Referencesmentioning

confidence: 99%

The effect of Lactobacillus casei and Bifidobacterium breve on antibiotic-associated diarrhea treatment: randomized double-blind clinical trial

Souza

Jorge

2012

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Introduction: Antibiotic-associated diarrhea (AAD) is an important side effect of this specific class of drugs. The objective of this study was to investigate the effect of the use of probiotics in the treatment of AAD. Methods: A group of hospitalized patients, who contracted diarrhea during or after 7 days of suspension of antimicrobial medication, was blindly randomized to receive a standardized diet associated with the use of the probiotics (Lactobacillus casei and Bifidobacterium breve) or its corresponding placebo, three times a day. Results: Seventy patients were studied. For the experimental (n=35) and control (n=35) groups, respectively, the average time of treatment was 5.06±2.18 and 5.49±3.17 days (p=0.95), and the average duration of diarrhea, among those who were healed, was 4.87±2.13 and 4.52±2.55 days (p=0.36). Four (11.4%) patients who received probiotics and ten (28.6%) who received the placebo were not cured (p=0.13), and relapse rates were similar between both groups. Seven patients from each group, in addition to diarrhea, presented cases of bloating and/or abdominal cramps and/or vomiting (p=1.00). Conclusions: In this light, it is concluded that L. casei associated with B. breve, in the administered dosage and frequency, has no effect on the antibiotic-associated diarrhea. Similar studies need to be conducted with higher doses of these or other probiotics. Keywords: Probiotics. Lactobacillus casei. Bifidobacterium breve. Antibiotic-associated diarrhea. RESUMO Introdução:A diarréia associada ao uso de antimicrobiano (DAA) é um importante efeito colateral dessa classe de fármacos. O objetivo do presente trabalho é investigar o efeito do uso de probióticos no tratamento da DAA. Métodos: Pacientes hospitalizados em um hospital universitário com diarréia, que se desenvolveu durante o uso ou até sete dias após a suspensão de antimicrobianos, foram randomizados, de forma cega, para receberem dieta padronizada associada, três vezes ao dia, ao uso de probiótico (Lactobacillus casei e Bifidobacterium breve) ou placebo. Resultados: Foram estudados um total de setenta pacientes. Para o grupo experimento (n=35) e controle (n=35), respectivamente, o tempo médio de tratamento foi de 5,06 ± 2,18 e 5,49 ± 3,17dias (p=0,95) e o tempo médio de duração da diarréia, entre aqueles que se curaram, foi de 4,87 ± 2,13 e 4,52 ± 2,55 dias (p=0,36). Quatro (11,4%) pacientes que receberam probióticos e dez (28,6%) que receberam placebo não foram curados (p=0,13) e a frequência de recidiva foi similar entre os grupos. Sete pacientes de cada grupo, além da diarréia, apresentaram distensão e/ou cólica abdominal e/ou vômito (p=1,00). Conclusões: L. casei associado a B. breve, na dosagem e frequência administradas, não demonstraram qualquer efeito no tratamento da diarréia associada a antimicrobiano. Estudos similares merecem ser realizados com doses maiores destes ou de outros probióticos. Palavras-chaves: Probióticos. Lactobacillus casei. Bifidobacterium breve. Diarréia associada ao uso de antimicrobiano.

show abstract

Prevention of antibiotic‐associated diarrhea in children by Clostridium butyricum MIYAIRI

Abstract: Clostridium butyricum MIYAIRI is effective for both the treatment and the prophylaxis of AAD in children, as it normalizes the intestinal flora disturbed by antibiotics.

Cited by 204 publications

References 7 publications

Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain

Inhibition of the cytotoxic effect of Clostridium difficile in vitro by Clostridium butyricum MIYAIRI 588 strain

Effects of dietary lipids and Clostridium butyricum on serum lipids and lipid-related gene expression in broiler chickens

The effect of Lactobacillus casei and Bifidobacterium breve on antibiotic-associated diarrhea treatment: randomized double-blind clinical trial

Contact Info

Product

Resources

About